Highlights and Quick Summary
Current Price to Tangible BV of PDL BioPharma, Inc. is 0.66 (as of December 30, 2019)
- Price to Tangible BV for the quarter ending June 29, 2020 was 0.77 (a 55.45% increase compared to previous quarter)
- Year-over-year quarterly Price to Tangible BV decreased by -13.31%
- Annual Price to Tangible BV for 2019 was 0.66 (a -52.57% decrease from previous year)
- Annual Price to Tangible BV for 2018 was 1.4 (a -11.9% decrease from previous year)
- Annual Price to Tangible BV for 2017 was 1.59 (a -45.85% decrease from previous year)
Visit stockrow.com/PDLI for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical Price to Tangible BV of PDL BioPharma, Inc.Most recent Price to Tangible BVof PDLI including historical data for past 10 years.
Interactive Chart of Price to Tangible BV of PDL BioPharma, Inc.
PDL BioPharma, Inc. Price to Tangible BV for the past 10 Years (both Annual and Quarterly)
Business Profile of PDL BioPharma, Inc.
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.